OPRXHealthcare · Health Information ServicesThe 6 Wall Street analysts covering OptimizeRx Corp. hold a median 12-month price target of $11 — +12.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OptimizeRx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (92): The business earns solid, repeatable profits on what it owns.
Volatility (27): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OPRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.0% from it.
Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | B. Riley Securities | Maintains | Buy | $10 → $11 |
| 14 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 14 Aug 2026 | Citizens | Maintains | Market Outperform | $9.00 → $11 |
| 13 May 2026 | B. Riley Securities | Maintains | Buy | — |
| 13 May 2026 | B. Riley Securities | Maintains | Buy | $11 → $10 |
| 13 May 2026 | Lake Street | Maintains | Buy | $20 → $11 |
| 13 May 2026 | Lake Street | Maintains | Buy | — |
| 13 May 2026 | Stephens & Co. | Maintains | Equal-Weight | $10 → $7.00 |
| 13 May 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 13 May 2026 | Stifel | Maintains | Buy | — |
| 13 May 2026 | Stifel | Maintains | Buy | $17 → $14 |
| 6 Mar 2026 | B. Riley Securities | Reiterates | Buy | — |
| 6 Mar 2026 | Lake Street | Maintains | Buy | — |
| 6 Mar 2026 | Roth Capital | Maintains | Buy | — |
| 6 Mar 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 6 Mar 2026 | Stifel | Maintains | Buy | — |
| 17 Nov 2025 | Stephens & Co. | Maintains | Equal-Weight | — |
| 7 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 10 Oct 2025 | JMP Securities | Maintains | Market Outperform | — |
| 11 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OPRX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, OptimizeRx Corp. returned −47.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 54% of US stocks
Cheaper than 58% of US stocks
Cheaper than 34% of US stocks
Higher than 9% of US stocks
Higher than 17% of US stocks
Higher than 88% of US stocks
Higher than 31% of US stocks
Higher than 59% of US stocks
Higher than 51% of US stocks
Higher than 72% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OptimizeRx Corp. has a market value of $175.8M and an enterprise value of $172.6M.
Revenue in the twelve months to 30 June 2026: $98.7M. The latest quarter shrank 29.8% year on year.
Net income over the same four quarters: $4.6M, a 4.7% net margin.
Diluted earnings per share, trailing twelve months: $0.23.
Free cash flow in the twelve months to 30 June 2026: $18.5M, after $217K of capital spending.
Trailing P/E: 39.0×; forward P/E: 9.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
OptimizeRx Corp. employs 132 people — $747K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OptimizeRx Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OptimizeRx announced that it will hold its third-quarter 2026 conference call on Wednesday, November 11, 2026, at 4:30 p.m. ET.
Why it matters — OPRX watchers can note the scheduled call, where the company will discuss its third-quarter 2026 results.
OptimizeRx and PulsePoint announced a DSP integration that expands buyer access to OptimizeRx’s point-of-care inventory through existing programmatic workflows.
Why it matters — OPRX watchers may note the partnership broadens the ways buyers can access the company’s point-of-care media inventory.
OptimizeRx announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making its authenticated point of care inventory directly available to advertisers using The Trade Desk's demand side platform. This brings net new authenticated healthcare professional reach to The Trade Desk.
Why it matters — This expands OptimizeRx's distribution of its authenticated HCP inventory to a major programmatic advertising platform, potentially broadening its advertiser reach.
OptimizeRx was upgraded to 'Buy' on an improved 2027 growth outlook and attractive valuation. The company reported Q2 2026 gross margin of 76.5%, marking five consecutive quarters of gains, and reaffirmed 2026 guidance of $95M–$100M revenue and $21M–$25M adjusted EBITDA.
Why it matters — For OPRX watchers, the article signals strengthening profitability through a shift to higher-margin offerings and a more favorable long-term outlook.
OptimizeRx has expanded its Natural Language Audience Builder to unify healthcare provider (HCP) and direct-to-consumer (DTC) audience intelligence into a single workflow. The new functionality enables DSPs and agency planners to create deterministic HCP and consumer audiences more quickly.
Why it matters — OPRX watchers would care because this product expansion strengthens OptimizeRx's audience-planning capabilities, potentially broadening its appeal to demand-side platforms and agencies.
The 6 Wall Street analysts covering OptimizeRx Corp. have a median 12-month price target of $11, with estimates ranging from $11 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering OptimizeRx Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OptimizeRx Corp. 85 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, OptimizeRx Corp. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (92 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +12.0% from the last close, and Ticker Nerd's factor model ranks OptimizeRx Corp. 85 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OptimizeRx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $18 over the next 12 months.
OptimizeRx Corp. returned -47.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
OptimizeRx Corporation is a healthcare technology company that helps life sciences organizations connect with healthcare professionals and patients through digital engagement tools. OptimizeRx Corporation’s current offerings include digital health messaging, electronic health record workflow solutions, financial messaging, patient education, brand messaging, and patient engagement services.
The most recent item we track (GlobeNewsWire, 28 Oct 2026): "OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET". OptimizeRx announced that it will hold its third-quarter 2026 conference call on Wednesday, November 11, 2026, at 4:30 p.m. ET.
OptimizeRx Corporation is a healthcare technology company that helps life sciences organizations connect with healthcare professionals and patients through digital engagement tools. OptimizeRx Corporation’s current offerings include digital health messaging, electronic health record workflow solutions, financial messaging, patient education, brand messaging, and patient engagement services. Its platform is designed to deliver timely clinical, educational, and access-related information at the point of care, supporting communication across pharmaceutical manufacturers, providers, and patients. The company operates within the healthcare information services and digital health market, where it plays a role in improving how treatment information and support resources are shared in clinical settings. Founded in 2006 and headquartered in Waltham, Massachusetts, OptimizeRx Corporation focuses on technology-enabled solutions for the healthcare communications ecosystem.
CEO Mr. Stephen L. Silvestro · 132 employees · United States · https://www.optimizerx.com
